- ICH GCP
- US Clinical Trials Registry
- Clinical Trial NCT04858828
Investigation on Predictive Molecular Markers of Efficacy for Front-line Immunochemotherapy in Advanced NSCLC
April 22, 2021 updated by: Zhou Chengzhi
Investigation on Molecular Markers Associated With the Clinical Efficacy of Immunotherapy Combined With Chemotherapy in the First-line Treatment of Patients With Advanced Non-small-cell Lung Cancer
This project is a real-world exploratory study aiming to explore potential molecular markers detectable at baseline that can enable the prediction of clinical efficacy of front-line immunotherapy combined with chemotherapy in advanced non-small cell lung cancer (NSCLC).
This study aims to include a total of 200 treatment-naïve patients initially diagnosed with advanced NSCLC.
Paired tissue and blood samples collected from all patients before the start of immunochemotherapy treatment (baseline) will be analyzed.
The patient samples will be submitted for molecular analysis, including next-generation sequencing (NGS)-based gene expression profiling (GEP) and inflammation-related T-cell receptor (TCR) repertoire profiling.
The molecular assay results will include but will not be limited to tumor mutation burden (TMB), microsatellite instability (MSI) status, DNA damage repair (DDR)-related gene mutation status, and programmed death-ligand 1 (PD-L1) expression level.
Patients will be followed-up for treatment responses until radiological confirmation of disease progression to first-line immunochemotherapy.
The molecular assay results will then be analyzed with clinical data including objective responses and progression-free survival outcomes, among others, to identify molecular markers at baseline that are associated with clinical efficacy of immunochemotherapy.
Study Overview
Status
Not yet recruiting
Conditions
Study Type
Observational
Enrollment (Anticipated)
200
Contacts and Locations
This section provides the contact details for those conducting the study, and information on where this study is being conducted.
Study Contact
- Name: Chengzhi Zhou
- Phone Number: 13560351186
- Email: doctorzcz@163.com
Study Locations
-
-
Guangdong
-
Guangzhou, Guangdong, China, 510120
- Zhou Chengzhi
-
-
Participation Criteria
Researchers look for people who fit a certain description, called eligibility criteria. Some examples of these criteria are a person's general health condition or prior treatments.
Eligibility Criteria
Ages Eligible for Study
18 years and older (Adult, Older Adult)
Accepts Healthy Volunteers
N/A
Genders Eligible for Study
All
Sampling Method
Probability Sample
Study Population
Patients with advanced NSCLC eligible for front-line treatment of immunotherapy combined with chemotherapy.
Description
Inclusion Criteria:
- Patients who are clinically diagnosed with stage IV NSCLC;
- Patients who submitted samples for molecular testing using the OncoScreen Plus panel and PD-L1 (22C3) immunohistochemistry test at baseline;
- Patients with negative results for sensitizing mutations for 6 genes, including EGFR, ALK, ROS1, BRAF, MET exon 14 skipping, and RET;
- Patients without contraindications for immunotherapy;
- Patients who are 18 years or older at the time of signing the informed consent form;
- Patients with life expectancy of at least 12 weeks;
- Patients with ECOG score of 0 or 1;
Patients with adequate organ function defined by the following criteria:
- Absolute neutrophil count ≥ 1.5109/L;
- Platelets ≥ 90109/L;
- Hemoglobin ≥ 9.0g/dL;
- Albumin levels ≥2.8 g/L;
- Total serum bilirubin ≤ 1.5 the upper limit of normal (ULN); for patients with liver metastases, total bilirubin ≤ 2 ULN;
- Serum alanine aminotransferase (ALT) and aspartate aminotransferase (AST) ≤ 2.5 ULN; for patients with liver metastases, ALT and AST ≤ 5ULN;
- Serum creatinine ≤ 1.5 ULN;
- International normalized ratio (INR) or plasma prothrombin time (PT) ≤1.5ULN.
Exclusion Criteria:
- Patients with other concurrent tumors;
- Patients with other concurrent medical conditions that may affect their follow-up and short-term survival;
- Patients with any history of immunotherapy;
- Patients with any history of chemotherapy, radiotherapy or other anti-tumor treatments;
- Patients with heart function classified as New York Heart Association (NYHA) class III or IV;
- Patients with peripheral nerve disease;
- Patients with confirmed hearing loss;
- Patients with other conditions deemed unsuitable for enrollment by the researchers.
Study Plan
This section provides details of the study plan, including how the study is designed and what the study is measuring.
How is the study designed?
Design Details
What is the study measuring?
Primary Outcome Measures
Outcome Measure |
Measure Description |
Time Frame |
---|---|---|
Investigation on molecular markers associated with the clinical efficacy of immunotherapy combined with chemotherapy in the first-line treatment of patients with advanced non-small-cell lung cancer
Time Frame: June 2021 - March 2024
|
Next-generation sequencing (NGS)-based gene expression profiling (GEP) and inflammation-related T-cell receptor (TCR) repertoire profiling.
The molecular assay results will include but will not be limited to tumor mutation burden (TMB), microsatellite instability (MSI) status, DNA damage repair (DDR)-related gene mutation status, and programmed death-ligand 1 (PD-L1) expression level.
|
June 2021 - March 2024
|
Collaborators and Investigators
This is where you will find people and organizations involved with this study.
Sponsor
Study record dates
These dates track the progress of study record and summary results submissions to ClinicalTrials.gov. Study records and reported results are reviewed by the National Library of Medicine (NLM) to make sure they meet specific quality control standards before being posted on the public website.
Study Major Dates
Study Start (Anticipated)
June 1, 2021
Primary Completion (Anticipated)
March 1, 2023
Study Completion (Anticipated)
March 1, 2024
Study Registration Dates
First Submitted
April 22, 2021
First Submitted That Met QC Criteria
April 22, 2021
First Posted (Actual)
April 26, 2021
Study Record Updates
Last Update Posted (Actual)
April 26, 2021
Last Update Submitted That Met QC Criteria
April 22, 2021
Last Verified
April 1, 2021
More Information
Terms related to this study
Other Study ID Numbers
- CROC2101
Drug and device information, study documents
Studies a U.S. FDA-regulated drug product
No
Studies a U.S. FDA-regulated device product
No
This information was retrieved directly from the website clinicaltrials.gov without any changes. If you have any requests to change, remove or update your study details, please contact register@clinicaltrials.gov. As soon as a change is implemented on clinicaltrials.gov, this will be updated automatically on our website as well.
Clinical Trials on Biomarkers
-
Peking UniversityCompleted
-
University of California, DavisUSDA, Western Human Nutrition Research CenterRecruiting
-
Harvard School of Public Health (HSPH)CompletedBiomarkersUnited States
-
West China HospitalRecruitingBiomarkers | NeonateChina
-
U.S. Army Medical Research and Development CommandWalter Reed Army Institute of Research (WRAIR)CompletedBiomarkers, PharmacologicalUnited States
-
Five Liters, Inc.Northwell Health; The Feinstein Institutes for Medical ResearchRecruitingHemostasis | Blood BiomarkersUnited States
-
CareDxActive, not recruitingLiver Transplantation | BiomarkersUnited States
-
Washington State UniversityEunice Kennedy Shriver National Institute of Child Health and Human Development... and other collaboratorsCompletedInteraction | Endogenous BiomarkersUnited States
-
University of MinnesotaCompleted
-
Dr Afchine FazelRecruitingEndometriosis (Diagnosis) | Blood Biomarkers | Endometrium BiomarkersFrance